GILEAD SCIENCES, INC. 8-K

What Happened

• Gilead Sciences, Inc. announced on May 20, 2026 that it entered into an Eleventh Supplemental Indenture to its March 30, 2011 base indenture and issued $3.0 billion aggregate principal amount of senior notes in a public offering registered on Form S-3. The offering closed following an underwriting agreement dated May 14, 2026 with Barclays, BofA Securities and Citigroup as representatives of the underwriters.

Key Details

• Total issued: $3.0 billion aggregate principal:
  • $500 million 4.250% Senior Notes due May 20, 2028
  • $1.0 billion 4.400% Senior Notes due May 20, 2029
  • $1.0 billion 4.600% Senior Notes due May 20, 2031
  • $500 million 4.900% Senior Notes due May 20, 2034
• Trustee: Computershare Trust Company, N.A., successor to Wells Fargo Bank, N.A.
• Use of proceeds: net proceeds for general corporate purposes, which may include acquisitions, investments or other strategic opportunities.
• Key covenant highlights: limitations on incurrence of secured indebtedness, sale-leaseback transactions, and certain mergers/consolidations/asset transfers; requirement to offer to repurchase notes upon specified change-of-control events; notes are redeemable at specified redemption prices.
• Related filings: underwriting agreement (Exhibit 1.1) and legal opinion of Sidley Austin LLP (Exhibit 5.1) filed with the 8-K.

Why It Matters

• The transaction creates $3.0 billion of new senior debt and establishes defined interest obligations (coupons and maturities) that will affect Gilead’s capital structure and future interest expense.
• Proceeds earmarked for general corporate purposes give the company flexibility to fund acquisitions or investments, but the new covenants and change-of-control repurchase obligations impose contractual limits on certain actions by the company and its subsidiaries.
• Retail investors should note the size, maturities and coupon rates of the notes when assessing Gilead’s leverage profile and cash-interest commitments going forward.